Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease

Jamalinia, Mohamad; Zare, Fatemeh; Noorizadeh, Kiarash; Bagheri Lankarani, Kamran

doi:10.1111/apt.17869

Cited by 2 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent research has revealed a correlation between metabolic dysfunction-associated steatotic liver disease (MASLD) and an increased risk of atherosclerosis [12][13][14][15]. This risk escalates proportionally with the severity of MASLD, particularly as brosis progresses [16,17]. Simultaneously, atherosclerosis emerges as a signi cant risk factor for the advancement of AAAs, thereby heightening the mortality risk among affected individuals [18,19].…”

Section: Introductionmentioning

confidence: 99%

Mortality Risk Associated with Liver Fibrosis in Patients Undergoing Abdominal Aortic Aneurysm Repair Surgery: A Longitudinal Study

Jamalinia,

Mirhosseini,

Ranjbar

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Abdominal Aortic Aneurysm (AAA) poses a significant health risk due to its silent nature and high mortality upon rupture. The Fib-4 index, initially designed for liver fibrosis assessment, presents potential beyond its scope. This study aims to investigate the correlation between FIB-4 and mortality risk, exploring its utility as a risk predictor for enhanced clinical management. This retrospective longitudinal research studied 141 AAA open repair surgery patients (92% male, mean age of 70 years (SD: 11.5)) from October 2016 to September 2021 for a median duration of 35 months of follow up (IQR: 0.7–56.6).All-cause mortality was the primary outcome. Hazard ratios (HR) were calculated for each Fib-4 cut-off between 1.5 and 3.25.FIB-4 cut-off range of 2.58–2.74 was associated with higher mortality risk in adjusted HR. Specifically, the HR for patients with a baseline FIB-4 ≥ 2.67 was 1.78 (95% CI: 1.06–3.00). Furthermore, FIB-4 ≥ 2.67 was significantly associated with a baseline aneurysm size ≥ 8cm [OR = 2.67 (95% CI: 1.17–6.09)].FIB-4 was independently associated with a higher mortality risk and higher aneurysm size. These findings suggest that FIB-4 assessment in clinical practice may enhance risk profiling, aiding in more precise stratification and management strategies for AAA patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Mortality Risk Associated with Liver Fibrosis in Patients Undergoing Abdominal Aortic Aneurysm Repair Surgery: A Longitudinal Study

Jamalinia,

Mirhosseini,

Ranjbar

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge

Jamalinia,

Lonardo

2024

Metab Target Organ Damage

Self Cite

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD) stands as an independent risk factor for cardiovascular disease (CVD), which is the leading cause of mortality among MASLD patients. The diverse spectrum of cardio-nephro-metabolic and vascular manifestations inherent in MASLD highlights the complex profile of CVD risk associated with this condition. However, current approaches to assessing CVD risk in MASLD lack specificity, predominantly relying on traditional markers. Although it is widely accepted that patients with advanced fibrosis are more prone to CVD risk, recent evidence suggests that this isolated focus may overlook the remarkable phenotypic variability of this CVD risk across the entire MASLD population. Emerging data indicate a progressive escalation of CVD risk in parallel with the severity of MASLD, highlighting the need for precise disease staging to inform accurate risk assessment. To address this challenge, we propose a novel sequential approach to CVD risk assessment in MASLD. While traditional CVD risk factors remain essential, incorporating liver-specific parameters enhances risk stratification and guides targeted interventions to mitigate the substantial burden of cardiovascular disease in this vulnerable population. This approach involves initial screening using FIB-4 and NAFLD fibrosis score, followed by assessment of liver fibrosis with imaging-based non-invasive techniques in individuals at intermediate-high risk for advanced fibrosis and liver fat quantification in low-risk individuals. Future prospective investigations should focus on the simultaneous use of liver biomarkers and imaging modalities to evaluate, in a sex-specific manner, the efficacy of the proposed approach and to determine optimal thresholds of liver fibrosis and steatosis for optimal CVD risk assessment.

show abstract

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease

Cited by 2 publications

References 46 publications

Mortality Risk Associated with Liver Fibrosis in Patients Undergoing Abdominal Aortic Aneurysm Repair Surgery: A Longitudinal Study

Mortality Risk Associated with Liver Fibrosis in Patients Undergoing Abdominal Aortic Aneurysm Repair Surgery: A Longitudinal Study

Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge

Contact Info

Product

Resources

About